Weiler E, Tuck M, Gonick H C
Clin Exp Hypertens A. 1985;7(5-6):809-36. doi: 10.3109/10641968509077229.
Previous investigations have demonstrated an increased amount of a sodium pump inhibitor (N.H.) in plasma from humans with essential hypertension and from animals with various forms of experimental hypertension. The present study has employed Sephadex column and C18 reverse phase separation of urines from patients with essential hypertension and normal controls to distinguish "high", "intermediate" and "low" molecular weight forms of N.H., measured through properties of Na-K-ATPase inhibition and digoxin-like immunoreactivity. The major difference between hypertensive and normotensive urines was a highly significant increase in the "intermediate" molecular weight form of N.H., as measured by Na-K-ATPase inhibition. In contrast, digoxin-like immunoreactivity was significantly decreased in urine from hypertensive patients. The results are compatible with an hypothesis that the defect in some forms of essential hypertension may be partial inhibition of enzymatic conversion of intermediate to final form of N.H., with the increased sodium pump inhibition primarily related to the precursor.
以往的研究表明,原发性高血压患者以及患有各种形式实验性高血压的动物血浆中钠泵抑制剂(N.H.)的含量有所增加。本研究采用葡聚糖凝胶柱和C18反相分离法,对原发性高血压患者和正常对照者的尿液进行分离,以区分N.H.的“高”、“中”、“低”分子量形式,并通过钠钾ATP酶抑制特性和地高辛样免疫反应性进行测定。高血压患者和血压正常者尿液的主要区别在于,通过钠钾ATP酶抑制测定,N.H.的“中等”分子量形式显著增加。相比之下,高血压患者尿液中的地高辛样免疫反应性显著降低。这些结果与一种假说相符,即某些形式的原发性高血压的缺陷可能是N.H.从中间形式到最终形式的酶促转化受到部分抑制,钠泵抑制增加主要与前体有关。